Ultrasound-aided drug delivery undergoes US trial:
This article was originally published in Clinica
Ekos has begun an FDA-approved Phase I clinical trial in the US to assess its ultrasound-enhanced drug delivery technology in the treatment of newly-formed clots in leg arteries. Preclinical studies have shown that simultaneously administering ultrasound and a clot-dissolving drug directly into the blocked area could dissolve a clot faster and more completely than using the drug alone. This is because ultrasound energy can help move the drug into hard-to-reach areas of the clot, said the Bothell, Washington-based company.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.